

# Hormone receptor-positive metastatic breast cancer: Tailoring patient care from ET-based approaches to ADCs

Thursday 15<sup>th</sup> May 2025, 12:45 – 13:45 (CEST)  
Room 13, International Congress Center Messe,  
Munich, Germany

**“Get your  
questions ready!”**

Join us as we delve into case studies to explore evolving approaches to personalise treatments for patients with HR+ mBC

## Join us for an interactive case-based discussion to:

- Discuss the recent and ongoing advancements from mBC clinical trials that look to extend the benefit of ET-based regimens and their implications for improving patient outcomes
- Explore how ADCs are transforming approaches to patient care across the mBC disease spectrum

## Faculty



**Prof. Sibylle Loibl (Chair)**  
Goethe University of Frankfurt,  
Germany



**Prof. François-Clément Bidard**  
Institut Curie,  
France



**Dr Sara Tolaney**  
Dana-Farber Cancer Institute,  
US

## Agenda

12:45 – 12:50	<b>HR-positive mBC:</b> Addressing a dynamic disease	Sibylle Loibl
12:50 – 13:05	<b>Exploring evolving ET-based regimens:</b> Recent advances and future directions	François-Clément Bidard
13:05 – 13:15	<b>Case-based discussion:</b> Personalising ET-based therapy	François-Clément Bidard Moderated by Sibylle Loibl
13:15 – 13:30	<b>ADCs:</b> Expanding options beyond ET	Sara Tolaney
13:30 – 13:40	<b>Case-based discussion:</b> Changing treatment modalities in HR-positive mBC	Sara Tolaney Moderated by Sibylle Loibl
13:40 – 13:45	<b>Summary and close</b>	Sibylle Loibl